Literature DB >> 14655848

Cognitive-behavioral therapy versus combined treatment with group psychoeducation and fluoxetine in bulimic outpatients.

V Ricca1, E Mannucci, B Mezzani, M Di Bernardo, E Barciulli, S Moretti, P L Cabras, C M Rotella.   

Abstract

A series of 51 female bulimic outpatients, aged 23.4+/-3.9, were assigned either to Cognitive-Behavioral Therapy (CBT) or combined Group Psychoeducation and Fluoxetine (GPF) treatment. The Eating Disorder Examination (EDE) was performed at the beginning of treatment and after 6 months, together with the administration of self reported questionnaires for depression (BDI) and Anxiety (STAI). A significant (p<0.001) reduction of the number of monthly binge episodes (from 25.0+/-12.9 to 6.2+/-3.8 and from 24.8+/-9.1 to 8.0+/-4.3) for CBT and GPF respectively were observed. Similar reductions were obtained in the number of episodes of compensatory behaviors. Both treatments reduced depression and anxiety (p<0.001) while CBT only determined a significative improvement of EDE scores. The data obtained suggest that GPF is as effective as CBT in reducing bulimic symptomatology but its long-term efficacy should be evaluated in a follow-up study.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 14655848     DOI: 10.1007/bf03339955

Source DB:  PubMed          Journal:  Eat Weight Disord        ISSN: 1124-4909            Impact factor:   4.652


  17 in total

1.  Cognitive-behavioral treatment of bulimia nervosa: a controlled evaluation.

Authors:  G T Wilson; E Rossiter; E I Kleifield; L Lindholm
Journal:  Behav Res Ther       Date:  1986

2.  Treatment of bulimia with bupropion: a multicenter controlled trial.

Authors:  R L Horne; J M Ferguson; H G Pope; J I Hudson; C G Lineberry; J Ascher; A Cato
Journal:  J Clin Psychiatry       Date:  1988-07       Impact factor: 4.384

3.  A comparison study of antidepressants and structured intensive group psychotherapy in the treatment of bulimia nervosa.

Authors:  J E Mitchell; R L Pyle; E D Eckert; D Hatsukami; C Pomeroy; R Zimmerman
Journal:  Arch Gen Psychiatry       Date:  1990-02

4.  A comparison of behavioral and cognitive-behavioral interventions for bulimia nervosa.

Authors:  D E Thackwray; M C Smith; J W Bodfish; A W Meyers
Journal:  J Consult Clin Psychol       Date:  1993-08

5.  Efficacy of a brief group psychoeducational intervention for bulimia nervosa.

Authors:  M P Olmsted; R Davis; D M Garner; M Eagle; W Rockert; M J Irvine
Journal:  Behav Res Ther       Date:  1991

6.  Fluoxetine versus placebo: a double-blind study with bulimic inpatients undergoing intensive psychotherapy.

Authors:  M M Fichter; K Leibl; W Rief; E Brunner; S Schmidt-Auberger; R R Engel
Journal:  Pharmacopsychiatry       Date:  1991-01       Impact factor: 5.788

7.  Bulimia nervosa: an ominous variant of anorexia nervosa.

Authors:  G Russell
Journal:  Psychol Med       Date:  1979-08       Impact factor: 7.723

8.  A prospective study of outcome in bulimia nervosa and the long-term effects of three psychological treatments.

Authors:  C G Fairburn; P A Norman; S L Welch; M E O'Connor; H A Doll; R C Peveler
Journal:  Arch Gen Psychiatry       Date:  1995-04

9.  Patients with bulimia nervosa who fail to engage in cognitive behavior therapy.

Authors:  S Coker; C Vize; T Wade; P J Cooper
Journal:  Int J Eat Disord       Date:  1993-01       Impact factor: 4.861

10.  Phenelzine vs placebo in 50 patients with bulimia.

Authors:  B T Walsh; M Gladis; S P Roose; J W Stewart; F Stetner; A H Glassman
Journal:  Arch Gen Psychiatry       Date:  1988-05
View more
  2 in total

1.  Predictors of dropout from in-patient treatment of eating disorders: an Italian experience.

Authors:  L Pingani; S Catellani; F Arnone; E De Bernardis; V Vinci; G Ziosi; G Turrini; M Rigatelli; S Ferrari
Journal:  Eat Weight Disord       Date:  2012-12       Impact factor: 4.652

Review 2.  The stepped-care approach in anorexia nervosa and bulimia nervosa: progress and problems.

Authors:  R Dalle Grave; V Ricca; T Todesco
Journal:  Eat Weight Disord       Date:  2001-06       Impact factor: 3.008

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.